MiMedx Group, Inc. (NASDAQ:MDXG) Receives Consensus Rating of “Buy” from Brokerages

MiMedx Group, Inc. (NASDAQ:MDXG) has been assigned a consensus rating of “Buy” from the five analysts that are currently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $12.00.

A number of equities research analysts have weighed in on MDXG shares. Craig Hallum reduced their target price on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 price objective on shares of MiMedx Group in a report on Thursday, August 1st.

MiMedx Group Stock Performance

NASDAQ:MDXG opened at $9.28 on Tuesday. The stock’s 50-day moving average is $6.30 and its 200-day moving average is $6.77. MiMedx Group has a 1-year low of $5.47 and a 1-year high of $9.48. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The stock has a market cap of $1.36 billion, a P/E ratio of 16.87 and a beta of 1.94.

Institutional Investors Weigh In On MiMedx Group

Large investors have recently modified their holdings of the company. Isthmus Partners LLC grew its stake in MiMedx Group by 30.4% during the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after purchasing an additional 91,714 shares during the period. Headlands Technologies LLC acquired a new stake in shares of MiMedx Group during the 1st quarter worth approximately $27,000. Blue Trust Inc. acquired a new stake in shares of MiMedx Group during the 3rd quarter worth approximately $30,000. Point72 Asset Management L.P. bought a new stake in shares of MiMedx Group in the 2nd quarter valued at $40,000. Finally, Point72 DIFC Ltd lifted its position in shares of MiMedx Group by 127.6% during the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after acquiring an additional 4,275 shares during the period. 79.15% of the stock is currently owned by institutional investors and hedge funds.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.